Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by capebretongirlon Jul 08, 2021 8:35pm
186 Views
Post# 33519360

RE:SZLS

RE:SZLSI like the looks of this and believe we are making headway - however the challenge of reality creeps in.

Who will use CARE and the AVRT program in the US (50 states) outside of the approximate 5000 patients already seen?  How will they discover this program once they fear they have cancer?  Why will they choose it over their current Doctor? The challenge equally exists with the other group of potential clients who have already been diagnosed with cancer as they will face the same issue - ie: why will they dump their medical go to and switch to CARE, particularly if they have no way of learning about it.?  Clearly now what is required is an IT solution to make CARE/AVRT a Google search friendly option so it is at least available as an option - otherwise it will remain unknown.  Yes, the 5000 patients and friends/families can potentially add patients, however for Aristotle and AVRT to flourish the way shareholders want - we will simply need more potential clients.

I hope to see a large effort on the IT side soon in order to address this issue and now is the time to get it going.



davewho wrote:

The AVRT  Program

AVRT™ is a comprehensive telehealth program that uses advanced diagnostics, evidence based clinical protocols and online physician supervision to help patients stay well and reduce the risk of developing cancer and other chronic diseases. AVRT is run by The Care Oncology Group, a team of experienced doctors and cancer specialists who can help you understand early warning signals for cancer and chronic diseases.
StageZero Life Sciences - StageZero Life Sciences Health Solutions
Interventions to Help Keep You Well - StageZero Life Sciences


<< Previous
Bullboard Posts
Next >>